Literature DB >> 24628500

Nodal distribution, stage migration due to diameter measurement and the prognostic significance of metastasis volume in melanoma sentinel lymph nodes: a validation study.

Rikke Riber-Hansen1, Stephen J Hamilton-Dutoit, Torben Steiniche.   

Abstract

To validate metastasis location, maximum metastasis diameter (MMD) measurement induced stage migration and the prognostic significance of total metastatic volume (TMV) in melanoma sentinel lymph nodes (SLNs). A new 227 patient SLN cohort examined by complete step sectioning (250 μm) was tested for TMV and MMD prognostic significance; metastasis location by three different three-level protocols (Central vs Peripheral vs Global); and potential treatment changing down-staging by two restricted five-level protocols [Reduced Central (250 μm) vs Reduced Even (500 μm) sections]. Both TMV and MMD independently predicted recurrence (TMV, hazard ratio (HR): 1.21; 95% confidence interval (CI) 1.07-1.37; p = 0.003; and MMD, HR: 1.46; 95% CI 1.08-1.98, p = 0.02) and melanoma-specific death (TMV, HR: 1.30; 95% CI 1.11-1.51; p = 0.001; and MMD, HR: 1.82; 95% CI 1.25-2.66, p = 0.002). The Central, Peripheral and Global protocols detected 72%, 76% and 83% of metastases found by complete step sectioning. Based on MMD, using the Reduced Central or Reduced Even protocols, potential treatment changing down-staging occurred in 20 (20%) or 13 (13%) of SLN-positive patients. This validation study establishes that: (i) metastases are globally located in melanoma SLNs; (ii) MMD but not TMV leads to uni-directional stage migration; and (iii) TMV analysis is of prognostic significance.
© 2014 APMIS. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Melanoma; image processing; lymphatic metastasis; sentinel lymph node biopsy

Mesh:

Year:  2014        PMID: 24628500     DOI: 10.1111/apm.12240

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  1 in total

Review 1.  [Sentinel node biopsy and lymph node dissection in the era of new systemic therapies for malignant melanoma].

Authors:  A Ulmer; L Kofler
Journal:  Hautarzt       Date:  2019-11       Impact factor: 0.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.